Five-Year Follow-Up of Choroidal Metastasis From Lung Adenocarcinoma Harboring Epidermal Growth Factor Receptor (EGFR) Mutation: A Case Report and Literature Review

TL;DR

A 71-year-old man with lung cancer and eye metastasis lived five years without recurrence after targeted and chemotherapy treatments.

Contribution

This case report provides a rare five-year follow-up of choroidal metastasis from EGFR-mutant lung cancer.

Findings

The patient's vision improved with afatinib as first-line treatment.

Choroidal metastasis did not recur for 61 months with sequential therapies.

Long-term management insights are offered for similar cases.

Abstract

This is a long-term follow-up case report of a 71-year-old man with lung adenocarcinoma and choroidal metastasis harboring an epidermal growth factor receptor mutation. Blurry vision, caused by the choroidal metastasis, improved with first-line treatment with afatinib. Thereafter, osimertinib was administered as a second-line treatment, then chemotherapy containing pemetrexed plus bevacizumab as a third-line treatment. For 61 months, recurrence of choroidal metastasis was absent.

Only a few reports of lung cancer with choroidal metastasis provide long-term follow-up of more than five years. Therefore, the clinical course of this patient may provide some insights for long-term management in such cases.

Figures